Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Pangea Biomed
Pangea Biomed Overview
Pangea Biomed is the developer of ENLIGHT, an advanced pan-cancer, pan-therapy response predictor. By combining machine learning, artificial intelligence, and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care. Pangea's unsupervised machine-learning approach makes ENLIGHT scalable and effective during the drug development process, when no clinical data is yet available.
Pangea is also developing EnlightDP, a response prediction technology based on the analysis of digital H&E slide images using its proprietary RNA expression imputation platform.
Pangea aims to bring effective precision oncology to cancer patients, improve oncology drug development, and empower oncologists to treat patients with success. Pangea is backed by NFX, and validations of its technology have been published in leading journals, including Med, Cell, Science Advances, Cancer Cell, and Nature Communications.
Pangea Biomed Adds $5M in Additional Funding for its Multi-Cancer Response Predictor Technology | BioPharma Dive
#Investment #Expand
Oct 15, 2022
www.precisiononcologynews.com
Pangea Biomed Nets Additional $5M in Seed Funds
#Investment #Expand
Apr 7, 2022
www.builtwithbiology.com
Pangea Biomed Launches with World's Most Advanced Multi-Cancer Response Predictor, Increasing Patient Benefits from Precision Oncology by 5x - SynBioBeta
Pangea Biomed Adds $5M in Additional Funding for its Multi-Cancer Response Predictor Technology | BioPharma Dive
#Investment #Expand
Oct 15, 2022
www.precisiononcologynews.com
Pangea Biomed Nets Additional $5M in Seed Funds
#Investment #Expand
Apr 7, 2022
www.builtwithbiology.com
Pangea Biomed Launches with World's Most Advanced Multi-Cancer Response Predictor, Increasing Patient Benefits from Precision Oncology by 5x - SynBioBeta
#Investment #Partners
View other companies you might be interested in
Pangea Biomed Team
No Data, yet.
Sorry, no content found under this section.
View other companies you might be interested in
Connect with
What is the reason for connecting? *
Your company *
Company website (recommended)
Please enter a valid website
Your organization type *
Please enter a valid organization type
Your position *
Add invitation message
0/300
Sending invitation...
Invitation sent
You will be able to start a conversation once [Name] accepts it.